SEARCH

SEARCH BY CITATION

References

  • Arno, P.S., K. Bonuck, and M. Davis. 1995. Rare Diseases, Drug Development, and AIDS: The Impact of the Orphan Drug Act. The Milbank Quarterly 73(2):23152.
  • AUTM (Association of University Technology Managers). 2002. The AUTM Licensing Survey 2002. Deerfield , IL .
  • AUTM (Association of University Technology Managers). 2009a. FY2008 US Licensing Survey. Available at http://www.autm.net (accessed June 16, 2011).
  • AUTM (Association of University Technology Managers). 2009b. Statement of Principles and Strategies for the Equitable Dissemination of Medical Technologies. Available at http://www.autm.net/Content/NavigationMenu/TechTransfer/GlobalHealth/statementofprincliples.pdf (accessed June 16, 2011).
  • Baker-Smith, C.M., D.K. Benjamin Jr., H.G. Grabowski, E.D. Reid, B. Mangum, J.V. Goldsmith, M.D. Murphy, R. Edwards, E.L. Eisenstein, J. Sun, R.M. Califf, and J.S. Li. 2008. Economic Returns of Pediatric Clinical Trials of Antihypertensive Drugs. American Heart Journal 156(4):68288.
  • Benjamin Jr., D.K., P.B. Smith, P. Jadhav, J.V. Gobburu, M.D. Murphy, V. Hasselblad, C. Baker-Smith, R.M. Califf, and J.S. Li. 2008. Pediatric Antihypertensive Trial Failures: Analysis of End Points and Dose Range. Hypertension 51(4):83440.
  • Benjamin Jr., D.K., P.B. Smith, M.D. Murphy, R. Roberts, L. Mathis, D. Avant, R.M. Califf, and J.S. Li. 2006. Peer-Reviewed Publication of Clinical Trials Completed for Pediatric Exclusivity. JAMA 296(10):126673.
  • Blumenthal, D., E.G. Campbell, M.S. Anderson, N. Causino, and K.S. Louis. 1997. Withholding Research Results in Academic Life Science. JAMA 277:122428.
  • Boots, I., R.N. Sukhai, R.H. Klein, R.A. Holl, J.M. Wit, A.F. Cohen, and J. Burggraaf. 2007. Stimulation Programs for Pediatric Drug Research—Do Children Really Benefit European Journal of Pediatrics 166(8):84955.
  • Bulut, H., and G. Moschini. 2009. U.S. Universities’ Net Returns from Patenting and Licensing: A Quantile Regression Analysis. Economic Innovation and New Technology 18(2):12337.
  • Cabri, P., and E.T. Tambuyzer. 2001. Orphan Medicinal Products: A Challenge from an Industry Point of View Pharmaceutical Policy and Law 3:4754.
  • Campbell, E.G., B.R. Clarridge, M. Gokhale, L. Birenbaum, S. Hilgartner, N.A. Holtzman, and D. Blumenthal. 2002. Data Withholding in Academic Genetics: Evidence from a National Survey. JAMA 287:47381.
  • Campbell, E.G., J.S. Weissman, N. Causino, and D. Blumenthal. 2000. Data Withholding in Academic Medicine: Characteristics of Faculty Denied Access to Research Results and Biomaterials. Research Policy 29:30312.
  • Caulfield, T., R.M. Cook-Deegan, F.S. Kieff, and J.P. Walsh. 2006. Evidence and Anecdotes: An Analysis of Human Gene Patenting Controversies. Nature Biotechnology 24:109194.
  • CBO (Congressional Budget Office). 1998. How Increased Competition from Generic Drugs Has Affected Prices and Returns in the Pharmaceutical Industry. Available at http://www.cbo.gov/ftpdocs/6xx/doc655/pharm.pdf (accessed June 16, 2011).
  • Cohen, W., R. Florida, L. Randazzese, and J. Walsh. 1998. Industry and the Academy: Uneasy Partners in the Cause of Technological Advance. In Challenges to the Research University, ed. R. Noll, 171200. Washington , DC : Brookings Institution.
  • Collins F. 2011. An audience with … Francis Collins. Interviewed by Asher Mullard. Nature Reviews: Drug Discovery 10(1):14.
  • Coté, T., A. Kelkar, K. Xu, M.M. Braun, and M.I. Phillips. 2010. Orphan Products: An Emerging Trend in Drug Approvals. Nature Reviews: Drug Discovery 9(1):84.
  • Davit, B.M., P.E. Nwakama, G.J. Buehler, D.P. Conner, S.H. Haidar, D.T. Patel, Y. Yang, L.X. Yu, and J. Woodcock. 2009. Comparing Generic and Innovator Drugs: A Review of 12 Years of Bioequivalence Data from the United States Food and Drug Administration. Annals of Pharmacotherapy 43(10):158397.
  • Denny, C.C., E.J. Emanuel, and S.D. Pearson. 2007. Why Well-Insured Patients Should Demand Value-Based Insurance Benefits. JAMA 297(22):251518.
  • DiMasi, J.A., and H.G. Grabowski. 2007. Economics of New Oncology Drug Development. Journal of Clinical Oncology 25:20916.
  • Eisenberg, R.S. 1996. Public Research and Private Development: Patents and Technology Transfer in Government-Sponsored Research. Virginia Law Review 82:16631727.
  • Engelberg, A.B. 1999. Special Patent Provisions for Pharmaceuticals: Have They Outlived Their Usefulness? IDEA Journal of Law & Technology 39:389426.
  • Epstein, R.A., and B. Kuhlik. 2004. Is There a Biomedical Anticommons Regulation 27:5458.
  • FDA (Food and Drug Administration). 1998. Guidance for Industry: 180-Day Generic Drug Exclusivity under the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act. Available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm079342.pdf (accessed June 16, 2011).
  • FDA (Food and Drug Administration). 2001. The Pediatric Exclusivity Provision: January 2001 Status Report to Congress. Available at http://www.fda.gov/downloads/drugs/developmentapprovalprocess/developmentresources/ucm049915.pdf (accessed June 16, 2011).
  • FDA (Food and Drug Administration). 2009. FDA Approves Coartem Tablets to Treat Malaria. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2009/ucm149559.htm (accessed June 16, 2011).
  • Frank, R.G. 2007. Regulation of Follow-On Biologics. New England Journal of Medicine 357:84143.
  • Frantz, S. 2006. Industry Sweats after Patent Verdict. Nature Reviews: Drug Discovery 5:44344.
  • FTC (Federal Trade Commission). 2002. Generic Drug Entry prior to Patent Expiration. Available at http://www.ftc.gov/os/2002/07/genericdrugstudy.pdf (accessed June 16, 2011).
  • GAO (General Accountability Office). 1987. Patent Policy: Recent Changes in Federal Law Considered Beneficial. GAO/RCED-87–44. Available at http://archive.gao.gov/t2pbat21/132994.pdf (accessed June 16, 2011).
  • GAO (General Accountability Office). 1998. Technology Transfer: Administration of the Bayh-Dole Act by Research Universities. GAO/RCED-98–126. Available at http://www.gao.gov/archive/1998/rc98126.pdf (accessed June 16, 2011).
  • GAO (Government Accountability Office). 2006. New Drug Development: Science, Business, Regulatory, and Intellectual Property Issues Cited as Hampering Drug Development Efforts. GAO-07–49. Available at http://www.gao.gov/new.items/d0749.pdf (accessed June 16, 2011).
  • Gingery, D. 2010. Waxman Says Biosimilar Pathway Will Push Applicants to BLA. Pink Sheet 72(47):112.
  • Goldman, D.P., A.E. Clarke, and A.M. Garber. 1992. Creating the Costliest Orphan: The Orphan Drug Act in the Development of Ceredase. International Journal of Technology Assessment in Health Care 8(4):58397.
  • Grabowski, H.G., and M. Kyle. 2007. Generic Competition and Market Exclusivity Periods in Pharmaceuticals. Managerial & Decision Economics 28(4/5):491502.
  • Grabowski, H.G., and J.M. Vernon. 1996. Longer Patents for Increased Generic Competition in the US. Pharmacoeconomics 10(suppl. 2):11023.
  • Grabowski, H.G., and J.M. Vernon. 2000. Effective Patent Life in Pharmaceuticals. International Journal of Technology Management 19:98120.
  • Grieve, J., J. Tordoff, D. Reith, and P. Norris. 2005. Effect of the Pediatric Exclusivity Provision on Children's Access to Medicines. British Journal of Clinical Pharmacology 59:73035.
  • Haffner, M.E. 2006. Adopting Orphan Drugs—Two Dozen Years of Treating Rare Diseases. New England Journal of Medicine 354(5):44547.
  • Hausman, N. 2011. Effects of University Innovation on Local Economic Growth and Entrepreneurship. Available at http://www.people.fas.harvard.edu/~hausman/Hausman_Univ_Innovation_1-23-2011.pdf (accessed June 16, 2011).
  • Heemstra, H.E., T.J. Giezen, A.K. Mantel-Teeuwisse, R.L. de Vrueh, and H.G. Leufkens. 2010. Safety-Related Regulatory Actions for Orphan Drugs in the US and EU: A Cohort Study. Drug Safety 33:12737.
  • Heemstra, H.E., H.G. Leufkens, R.P. Rodgers, K. Xu, B.C. Voordouw, and M.M. Braun. 2011. Characteristics of Orphan Drug Applications That Fail to Achieve Marketing Approval in the USA. Drug Discovery Today 16:7380.
  • Heemstra, H.E., S. van Weely, H.A. Büller, H.G. Leufkens, and R.L. de Vrueh. 2009. Translation of Rare Disease Research into Orphan Drug Development: Disease Matters. Drug Discovery Today 14:116673.
  • Heller, M.A., and R.S. Eisenberg. 1998. Can Patents Deter Innovation? The Anticommons in Biomedical Research. Science 280:698701.
  • Hemphill, C.S. 2006. Paying for Delay: Pharmaceutical Patent Settlement as a Regulatory Design Problem. NYU Law Review 81:15531623.
  • Hemphill, C.S., and B.N. Sampat. 2011. Evergreening, Patent Challenges, and Effective Market Life in Pharmaceuticals. Columbia Law and Economics Working Paper No. 399.
  • Henderson, R., A.B. Jaffe, and M. Trajtenberg. 2001. Universities as a Source of Commercial Technology: A Detailed Analysis of University Patenting: 1965–1988. Review of Economics & Statistics 80:11927.
  • Higgins, M.J., and S.J.H. Graham. 2009. Balancing Innovation and Access: Patent Challenges Tip the Scales. Science 326:37072.
  • Holden, C. 2007. Patent Office Casts Doubt on Wisconsin Stem Cell Patents. Science 316:812.
  • Hollis, A., and T. Pogge. 2008. The Health Impact Fund: Making New Medicines Accessible for All. New Haven , CT : Incentives for Global Health.
  • Jaffe, A.B. 1999. Measurement Issues. In Investing in Innovation: Creating a Research and Innovation Policy That Works, ed. L.M. Branscomb and J.H. Keller, 6484. Cambridge , MA : MIT Press.
  • Jensen, R., and M. Thursby. 2001. Proofs and Prototypes for Sale: The Licensing of University Inventions. American Economic Review 91:24059.
  • Joppi, R., V. Bertele, and S. Garattini. 2006. Orphan Drug Development Is Not Taking Off. British Journal of Clinical Pharmacology 67(5):494502.
  • Kapczynski, A., S. Chaifetz, Z. Katz, and Y. Benkler. 2005. Addressing Global Health Inequities: An Open Licensing Approach for University Innovations. Berkeley Technology Law Journal 20(2):10311114.
  • Kesselheim, A.S. 2008. Encouraging Drug Development for Neglected Diseases—The Trouble with FDA Review Vouchers. New England Journal of Medicine 359(19):19813.
  • Kesselheim, A.S. 2010a. Innovation and the Orphan Drug Act, 1983–2009: The Regulatory and Clinical Characteristics of Approved Orphan Drugs. In Accelerating Rare Diseases Research and Orphan Product Development, ed. M.J. Field and T.F. Boat, 291308. Washington , DC : National Academies Press.
  • Kesselheim, A.S. 2010b. Using Market Exclusivity Incentives to Promote Pharmaceutical Innovation. New England Journal of Medicine 363:185562.
  • Kesselheim, A.S., L. Murtagh, and M.M. Mello. 2011. The Controversy over “Pay-for-Delay” Settlements of Pharmaceutical Patent Disputes. New England Journal of Medicine (in press).
  • Kesselheim, A.S., J.A. Myers, and J. Avorn. 2011. Characteristics of Clinical Trials to Support Approval of Orphan vs. Nonorphan Drugs for Cancer. JAMA 305:232026.
  • Keyhani, S., M. Diener-West, and N. Powe. 2006. Are Development Times for Pharmaceuticals Increasing or Decreasing? Health Affairs 25:46168.
  • Li, J.S., E.L. Eisenstein, H.G. Grabowski, E.D. Reid, B. Mangum, K.A. Schulman, J.V. Goldsmith, M.D. Murphy, R.M. Califf, and D.K. Benjamin Jr. 2007. Economic Return of Clinical Trials Performed under the Pediatric Exclusivity Program. JAMA 297(5):48088.
  • Lichtenberg, F.R., and J. Waldfogel. 2003. Does Misery Love Company? Evidence from Pharmaceutical Markets before and after the Orphan Drug Act. NBER Working Paper Series (No. 9750), National Bureau of Economic Research, Inc.
  • Liebowitz, J. 2009. “Pay-for-Delay” Settlements in the Pharmaceutical Industry: How Congress Can Stop Anticompetitive Conduct, Protect Consumers’ Wallets, and Help Pay for Health Care Reform (the $35 Billion Solution). Available at http://www.ftc.gov/speeches/leibowitz/090623payfordelayspeech.pdf (accessed June 16, 2011).
  • Lourie, A. 1989. A Review of Recent Patent Term Extension Data. Journal of the Patent and Trademark Office Society 71:17176.
  • Maher, P.D., and M. Haffner. 2006. Orphan Drug Designation and Pharmacogenomics: Options and Opportunities. Biodrugs 20(2):7179.
  • Maragakis, L.L., E.N. Perencevich, and S.E. Cosgrove. 2008. Clinical and Economic Burden of Antimicrobial Resistance. Expert Review of Anti-Infective Therapy 6(5):75163.
  • Miller, H.I., and G. Conko. 2007. Dying for FDA Reform. CEI On Point 116:18.
  • Milne, C.-P. 2002. FDAMA's Pediatric Studies Incentive. Food and Drug Law Journal 57:491516.
  • Milne, C.-P., and J.B. Bruss. 2008. The Economics of Pediatric Formulation Development for Off-Patent Drugs. Clinical Therapeutics 30(11):213345.
  • Milne, C.-P., and L. Faden. 2007. Pediatric Study Costs Increased 8-Fold since 2000 as Complexity Level Grew. Tufts CSDD Impact Report 9(2):14.
  • Mitsumoto, J., E.R. Dorsey, C.A. Beck, K. Kieburtz, and R.C. Griggs. 2009. Pivotal Studies of Orphan Drugs Approved for Neurological Diseases. Annals of Neurology 66(2):18490.
  • Mowery, D.C., R.R. Nelson, B.N. Sampat, and A.A. Ziedonis. 2001. The Growth of Patenting and Licensing by U.S. Universities: An Assessment of the Effects of the Bayh-Dole Act of 1980. Research Policy 30:99119.
  • Mowery, D.C., R.R. Nelson, B.N. Sampat, and A.A. Ziedonis. 2004. Ivory Tower and Industrial Innovation: University-Industry Technology Transfer before and after the Bayh-Dole Act. Stanford , CA : Stanford Business Books.
  • Mowery, D.C., and B.N. Sampat. 2001. University Patents and Patent Policy Debates in the USA, 1925–1980. Industrial and Corporate Change 10:781814.
  • Mowery, D.C., and A.A. Ziedonis. 2000. Numbers, Quality, and Entry: How Has the Bayh-Dole Act Affected U.S. Patenting and Licensing? In Innovation Policy and the Economy, ed. A.B. Jaffe, J. Lerner, and S. Stern, 187220. Cambridge , MA : MIT Press.
  • Mowery, D.C., and A.A. Ziedonis. 2002. Academic Patent Quality and Quantity before and after the Bayh-Dole Act in the United States. Research Policy 31:399418.
  • Murray, F.R., and S. Stern. 2007. Do Formal Intellectual Property Rights Hinder the Free Flow of Scientific Knowledge? An Empirical Test of the Anti-Commons Hypothesis. Journal of Economic Behavior and Organization 63:64887.
  • NIH (National Institutes of Health) and Pharmaceutical Manufacturers Association. 1988. Report on the National Conference of Orphan Drugs: The Path to Promise. Washington , DC .
  • National Research Council. 2010. Managing University Intellectual Property in the Public Interest. Washington , DC : National Academies Press.
  • Nwaka, S., and A. Hudson. 2006. Innovative Lead Discovery Strategies for Tropical Diseases. Nature Reviews: Drug Discovery 5:94155.
  • Office of the Inspector General. 2001. The Orphan Drug Act: Implementation and Impact (OEI-09-00-00380). Available at http://oig.hhs.gov/oei/reports/oei-09-00-00380.pdf (accessed June 16, 2011).
  • Office of Science and Technology Policy. 2008. The Science of Science Policy: A Federal Research Roadmap. Available at http://scienceofsciencepolicy.net/sites/all/themes/sosp_theme3/userfiles/SoSP_Roadmap.pdf (accessed June 16, 2011).
  • Peabody, J.W., A. Ruby, and P. Cannon. 1995. The Economics of Orphan Drug Policy in the US: Can the Legislation Be Improved? Pharmacoeconomics 8(5):37484.
  • Pressman, L., R. Burgess, R.M. Cook-Deegan, S.J. McCormack, I. Nami-Wolk, M. Soucy, and L. Walters. 2006. The Licensing of DNA Patents by US Academic Institutions: An Empirical Survey. Nature Biotechnology 24:3139.
  • Public Citizen. 2001. Patently Offensive: Congress Set to Extend Monopoly Patents for Cipro and Other Drugs. Available at http://www.citizen.org/documents/ACF34F.PDF (accessed June 16, 2011).
  • Rai, A.K., J.H. Reichman, P.F. Uhlir, and C. Crossman. 2008. Pathways across the Valley of Death. Yale Journal of Health Policy Law & Ethics 8:136.
  • Reichert, J.M. 2003. Trends in Development and Approval Times for New Therapeutics in the United States. Nature Reviews: Drug Discovery 2:695702.
  • Ridley, D.B., H.G. Grabowski, and J.L. Moe. 2006. Developing Drugs for Developing Countries. Health Affairs 25:31324.
  • Roberts, R., W. Rodriguez, D. Murphy, and T. Crescenzi. 2003. Pediatric Drug Labeling: Improving the Safety and Efficacy of Pediatric Therapies. JAMA 290(7):90511.
  • Rodriguez, W., A. Selen, D. Avant, C. Chaurasia, T. Crescenzi, G. Gieser, J. Di Giacinto, S.M. Huang, P. Lee, L. Mathis, D. Murphy, S. Murphy, R. Roberts, H.C. Sachs, S. Suarez, V. Tandon, and R.S. Uppoor. 2008. Improving Pediatric Dosing through Pediatric Initiatives: What We Have Learned. Pediatrics 121(3):53039.
  • Sampat, B.N. 2009. Academic Patents and Access to Medicines in Developing Countries. American Journal of Public Health 99(1):917.
  • Sampat, B.N., and F.R. Lichtenberg. 2011. What are the Respective Roles of the Public and Private Sectors in Pharmaceutical Innovation? Health Affairs 30(2):3329.
  • Schacht, W.H. 2005. The Bayh-Dole Act: Selected Issues in Patent Policy and the Commercialization of Technology. CRS Report for Congress. Washington , DC : Congressional Research Service.
  • Scharf, S.F. 1989. Orphan Drugs: The Question of Product Liability. American Journal of Law and Medicine 10:491513.
  • Seoane-Vazquez, E., R. Rodriguez-Monguio, S.L. Szeinbach, and J. Visaria. 2008. Incentives for Orphan Drug Research and Development in the United States. Orphanet: Journal of Rare Diseases 3:33.
  • Seoane-Vazquez, E., S. Schondelmeyer, and S.L. Szeinbach. 2008. Drug Patent Life and Generic Entry: Analysis of the New Molecular Entities Approved by the FDA between 1980 and 1999. Journal of Pharmaceutical Finance, Economics and Policy 16:6785.
  • Shane, S. 2004. Encouraging University Entrepreneurship? The Effect of the Bayh-Dole Act on University Patenting in the United States. Journal of Business Venturing 19:12751.
  • Shrank, W.H., N.K. Choudhry, J. Agnew-Blais, A.D. Federman, J.N. Liberman, J. Liu, A.S. Kesselheim, M.A. Brookhart, and M.A. Fischer. 2010. State Generic Substitution Laws Can Lower Drug Outlays under Medicaid. Health Affairs 29(7):138390.
  • Shulman, S.R., B. Bienz-Tadmor, P.S. Seo, J.A. DiMasi, L. Lasagna. 1992. Implementation of the Orphan Drug Act: 1983–1991. Food and Drug Law Journal 47(4):363403.
  • Shulman, S.R., J.A. DiMasi, and K.I. Kaitin. 1999. Patent Term Restoration—The Impact of the Hatch-Waxman Act on New Drugs and Biologics Approved, 1984–1995. Journal of Biolaw & Business 2:6368.
  • Shulman, S.R., and M. Manocchia. 1997. The US Orphan Drug Programme 1983–1995. Pharmacoeconomics 12(3):31226.
  • Singh, A.K., L. Szczech, K.L. Tang, H. Barnhart, S. Sapp, M. Wolfson, and D. Reddan. 2006. Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease. New England Journal of Medicine 355(20):208598.
  • Smith, P.B., D.K. Benjamin Jr., M.D. Murphy, R. Johann-Liang, S. Iyasu, B. Gould, R.M. Califf, J.S. Li, and W. Rodriguez. 2008. Safety Monitoring of Drugs Receiving Pediatric Marketing Exclusivity. Pediatrics 122(3):e62833.
  • So, A.D., B.N. Sampat, A.K. Rai, R. Cook-Deegan, J.H. Reichman, R. Weissman, and A. Kapczynski. 2008. Is Bayh-Dole Good for Developing Countries? Lessons from the US Experience. PLoS Biology 286(10):e262.
  • Sobolski, G.K., J.H. Barton, and E.J. Emanuel. 2005. Technology Licensing: Lessons from the US Experience. JAMA 294:313740.
  • Spellberg, B., R. Guidos, D. Gilbert, J. Bradley, H.W. Boucher, W.M. Scheld, J.G. Bartlett, and J. Edwards. 2008. The Epidemic of Antibiotic-Resistant Infections: A Call to Action for the Medical Community from the Infectious Diseases Society of America. Clinical Infectious Diseases 46:15564.
  • Sridhara, R., J.R. Johnson, R. Justice, P. Keegan, A. Chakravarty, and R. Pazdur. 2010. Review of Oncology and Hematology Drug Product Approvals at the US Food and Drug Administration between July 2005 and December 2007. Journal of the National Cancer Institute 102(4):23043.
  • Stevens, A.J., J.J. Jensen, K. Wyller, P.C. Kilgore, S. Chatterjee, and M.L. Rohrbaugh. 2011. The Role of Public-Sector Research in the Discovery of Drugs and Vaccines. New England Journal of Medicine 364:53541.
  • Szefler, S.J., G. Whelan, M. Gleason, and J.D. Spahn. 2003. The Need for Pediatric Studies of Allergy and Asthma Medications. Current Allergy Asthma Reports 3:47883.
  • Thursby, J., and M. Thursby. 2008. Knowledge Creation and Diffusion of Public Science with Intellectual Property Rights. In Intellectual Property Rights and Technical Change, by K.E. Maskus, 199232. Frontiers in Economics Series, vol. 2. Amsterdam : Elsevier Press.
  • Trouiller, P., C. Battistella, J. Pinel, and B. Pecoul. 1999. Is Orphan Drug Status Beneficial to Tropical Disease Control? Comparison of the American and Future European Orphan Drug Acts. Tropical Medicine & International Health 4(6):41220.
  • Trouiller, P., P. Olliaro, E. Torreele, J. Orbinski, R. Laing, and N. Ford. 2002. Drug Development for Neglected Diseases: A Deficient Market and a Public-Health Policy Failure. The Lancet 359:218894.
  • Villa, S., A. Compagni, and M.R. Reich. 2009. Orphan Drug Legislation: Lessons for Neglected Tropical Diseases. International Journal of Health Planning and Management 24(1):2742.
  • Walsh, J.P., A. Arora, and W.M. Cohen. 2003. Working through the Patent Problem. Science 299:1021.
  • Walsh, J.P., C. Cho, and W.M. Cohen. 2005. View from the Bench: Patents and Material Transfers. Science 309:20023.
  • Walsh, J.P., W.M. Cohen, and A. Arora. 2003. Patenting and Licensing of Research Tools and Biomedical Innovation. In Patents in the Knowledge-Based Economy, ed. W.M. Cohen and S.A. Merrill, 285340. Washington , DC : National Academies Press.
  • Walsh, J.P., and W. Hong. 2003. Secrecy Is Increasing in Step with Competition. Nature 422:8012.
  • Walton, S.M., G.T. Schumock, K.V. Lee, G.C. Alexander, D. Meltzer, and R.S. Stafford. 2008. Prioritizing Future Research on Off-Label Prescribing: Results of a Quantitative Evaluation. Pharmacotherapy 28(12):144352.
  • Wellman-Labadie, O., and Y. Zhou. 2010. The US Orphan Drug Act: Rare Disease Research Stimulator or Commercial Opportunity? Health Policy 95(2/3):21628.
  • Wheadon, D.E. 2010. Market Exclusivity for Biologics. New England Journal of Medicine 362:661.
  • Williams, H.L. 2010. Intellectual Property Rights and Innovation: Evidence from the Human Genome. NBER Working Paper Series (w16213). Available at http://papers.ssrn.com/sol3/papers.cfm?abstract_id=1648013 (accessed June 16, 2011).
  • Wilson, J.T. 1999. An Update on the Therapeutic Orphan. Pediatrics 104:58590.
  • Yin, W. 2008. Market Incentives and Pharmaceutical Innovation. Journal of Health Economics 27(4):106077.
  • Yin, W. 2009. R&D Policy, Agency Costs and Innovation in Personalized Medicine. Journal of Health Economics 28(5):95062.